SB-435495

• Description:

  SB-435495 is a potent, selective, reversible, non-covalent and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM[1][3].

• UNSPSC:

  12352005

• Target:

  Phospholipase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/sb-435495.html

• Purity:

  99.71

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(N(CCN(CC)CC)CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)CN(C(SCC3=CC=C(F)C=C3)=N4)C=C(CC5=CN(C)N=C5)C4=O

• Molecular Formula:

  C38H40F4N6O2S

• Molecular Weight:

  720.82

• References & Citations:

  [1]Blackie JA, et al. The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A (2) for evaluation in man. Bioorg Med Chem Lett. 2002 Sep 16;12 (18) :2603-6.|[2]Yang L, et al. AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis. Exp Ther Med. 2017 Apr;13 (4) :1622-1629.|[3]Canning P, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. Proc Natl Acad Sci U S A. 2016 Jun 28;113 (26) :7213-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  Phospholipase A

• CAS Number:

  304694-39-1